Cargando…

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

BACKGROUND: This study investigated the survival benefits of sorafenib vs. radiotherapy (RT) in patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in the main trunk or the first branch. METHODS: Ninety-seven patients were retrospectively reviewed. Forty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakazawa, Takahide, Hidaka, Hisashi, Shibuya, Akitaka, Okuwaki, Yusuke, Tanaka, Yoshiaki, Takada, Juichi, Minamino, Tsutomu, Watanabe, Masaaki, Kokubu, Shigehiro, Koizumi, Wasaburo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014748/ https://www.ncbi.nlm.nih.gov/pubmed/24886354 http://dx.doi.org/10.1186/1471-230X-14-84

Ejemplares similares

Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report
por: Okuwaki, Yusuke, et al.
Publicado: (2012)

Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases
por: Nakazawa, Takahide, et al.
Publicado: (2010)

Peliosis hepatis disseminated rapidly throughout the liver in a patient with prostate cancer: a case report
por: Hidaka, Hisashi, et al.
Publicado: (2015)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

A suspected case of Clostridium perfringens sepsis with intravascular hemolysis after transhepatic arterial chemoembolization: a case report
por: Uojima, Haruki, et al.
Publicado: (2019)

Undifferentiated Embryonal Sarcoma of the Liver Identified after the Initial Diagnosis of a Hepatic Cyst
por: Manabe, Yusaku, et al.
Publicado: (2020)

Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis
por: Uojima, Haruki, et al.
Publicado: (2017)

Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report
por: Jiang, Weimin, et al.
Publicado: (2014)

Cartilage-hair Hypoplasia Complicated with Liver Cirrhosis Due to Chronic Intrahepatic Cholestasis
por: Kogami, Taro, et al.
Publicado: (2021)

The Diagnosis of Drug-induced Liver Injury: Current Diagnostic Ability and Future Challenges of the Digestive Disease Week-Japan 2004 Scale 15 Years after Its Proposal
por: Watanabe, Masaaki, et al.
Publicado: (2021)

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2020)

Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2021)

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
por: Kondo, Masaaki, et al.
Publicado: (2019)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Intraperitoneal bleeding after balloon-occluded retrograde transvenous obliteration: a case report
por: Furue, Yasuaki, et al.
Publicado: (2015)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Splenectomy for Torsion of a Wandering Spleen in a Patient with Myeloproliferative Disease
por: Imawari, Kana, et al.
Publicado: (2021)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis
por: Burney, Ikram A., et al.
Publicado: (2021)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Endoscopic ultrasound-guided antegrade metal stent placement using the stent-in-stent technique in a patient with malignant hilar biliary obstruction
por: Yamauchi, Hiroshi, et al.
Publicado: (2018)

Long-lasting patent fistula after EUS-guided choledochoduodenostomy in a patient with refractory benign biliary stricture
por: Iwai, Tomohisa, et al.
Publicado: (2018)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Clinical implications of doubling time of gastrointestinal submucosal tumors
por: Koizumi, Shuko, et al.
Publicado: (2016)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
por: Danilovic, Debora L. S., et al.
Publicado: (2018)

The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency
por: Shao, Xue, et al.
Publicado: (2022)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
por: Sasaki, Yasutsuna, et al.
Publicado: (2014)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h83vsmkn3a6g4vjpmgck14ds26